NO174510B - Anlogifremgangsmaate for fremstilling av terapeutisk aktivt 9-(2- fosfonylmethoxyethyl)-adenin - Google Patents
Anlogifremgangsmaate for fremstilling av terapeutisk aktivt 9-(2- fosfonylmethoxyethyl)-adenin Download PDFInfo
- Publication number
- NO174510B NO174510B NO861621A NO861621A NO174510B NO 174510 B NO174510 B NO 174510B NO 861621 A NO861621 A NO 861621A NO 861621 A NO861621 A NO 861621A NO 174510 B NO174510 B NO 174510B
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compounds
- adenine
- dimethylformamide
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- -1 methylene, ethylene, propylene, ethylidene, methoxyethylene, benzyloxyethylene Chemical group 0.000 claims abstract description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 8
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 8
- 239000012312 sodium hydride Substances 0.000 claims description 8
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 claims description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- SUPKOOSCJHTBAH-UHFFFAOYSA-N adefovir Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000003456 ion exchange resin Substances 0.000 claims description 5
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- LVOASXNJWPROPP-UHFFFAOYSA-N (4-methylphenyl)sulfonyloxymethylphosphonic acid Chemical compound CC1=CC=C(S(=O)(=O)OCP(O)(O)=O)C=C1 LVOASXNJWPROPP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- VAQOTZQDXZDBJK-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)ethanol Chemical compound NC1=NC=NC2=C1N=CN2CCO VAQOTZQDXZDBJK-UHFFFAOYSA-N 0.000 claims description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 3
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract description 2
- UAYCAARGGQRWMQ-UHFFFAOYSA-N 1-ethenoxy-1-ethoxyethane Chemical group CCOC(C)OC=C UAYCAARGGQRWMQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 229930024421 Adenine Natural products 0.000 description 9
- 229960000643 adenine Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003559 chemosterilizing effect Effects 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 150000000180 1,2-diols Chemical class 0.000 description 1
- JBTYCAYQBLWDEV-UHFFFAOYSA-N 3-(6-aminopurin-9-yl)-2-methoxypropan-1-ol Chemical compound N1=CN=C2N(CC(CO)OC)C=NC2=C1N JBTYCAYQBLWDEV-UHFFFAOYSA-N 0.000 description 1
- BKLZHVCAEBYXHN-UHFFFAOYSA-N 3-(6-aminopurin-9-yl)propoxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2CCCOCP(O)(O)=O BKLZHVCAEBYXHN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- TYBWABJIIOVYOR-UHFFFAOYSA-N OCC(C(O)=O)OP(=O)=O Chemical compound OCC(C(O)=O)OP(=O)=O TYBWABJIIOVYOR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- FZXSSJIKXCFPDP-UHFFFAOYSA-N chloro(dichlorophosphoryl)methane Chemical compound ClCP(Cl)(Cl)=O FZXSSJIKXCFPDP-UHFFFAOYSA-N 0.000 description 1
- MOFCYHDQWIZKMY-UHFFFAOYSA-N chloromethylphosphonic acid Chemical compound OP(O)(=O)CCl MOFCYHDQWIZKMY-UHFFFAOYSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- WGQMNJYLZXTHIN-UHFFFAOYSA-N dimethoxyphosphorylmethyl 4-methylbenzenesulfonate Chemical compound COP(=O)(OC)COS(=O)(=O)C1=CC=C(C)C=C1 WGQMNJYLZXTHIN-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000654 isopropylidene group Chemical class C(C)(C)=* 0.000 description 1
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Inorganic materials [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS853017A CS263951B1 (en) | 1985-04-25 | 1985-04-25 | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO861621L NO861621L (no) | 1986-10-27 |
| NO174510B true NO174510B (no) | 1994-02-07 |
| NO174510C NO174510C (Direct) | 1994-05-18 |
Family
ID=5369028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO861621A NO174510B (no) | 1985-04-25 | 1986-04-24 | Anlogifremgangsmaate for fremstilling av terapeutisk aktivt 9-(2- fosfonylmethoxyethyl)-adenin |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4808716A (Direct) |
| EP (1) | EP0206459B1 (Direct) |
| JP (1) | JPS61275289A (Direct) |
| AT (1) | ATE78259T1 (Direct) |
| AU (1) | AU580151B2 (Direct) |
| CA (1) | CA1295614C (Direct) |
| CS (1) | CS263951B1 (Direct) |
| DE (1) | DE3686002T2 (Direct) |
| DK (1) | DK173625B1 (Direct) |
| EG (1) | EG18079A (Direct) |
| HK (1) | HK213296A (Direct) |
| NO (1) | NO174510B (Direct) |
| NZ (1) | NZ215925A (Direct) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047533A (en) * | 1983-05-24 | 1991-09-10 | Sri International | Acyclic purine phosphonate nucleotide analogs |
| US4845084A (en) * | 1984-01-26 | 1989-07-04 | Merck & Co., Inc. | Phosphate derivatives of substituted butyl guanines, antiviral compositions containing them, and methods of treating viral infections with them |
| CS264222B1 (en) * | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
| US5650510A (en) * | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
| IL84477A (en) * | 1986-11-18 | 1995-12-08 | Bristol Myers Squibb Co | History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them |
| US5247085A (en) * | 1987-11-30 | 1993-09-21 | Beecham Group P.L.C. | Antiviral purine compounds |
| IL88518A (en) * | 1987-11-30 | 1994-02-27 | Beecham Group Plc | 3-(phosphoryl methoxyethoxy) -purine derivatives, their preparation and pharmaceutical compositions containing them |
| EP0335770B1 (en) * | 1988-04-01 | 1997-01-15 | Merrell Pharmaceuticals Inc. | Novel fluorophosphonate nucleotide derivatives |
| EP0339161A1 (en) * | 1988-04-01 | 1989-11-02 | Merrell Dow Pharmaceuticals Inc. | Novel fluorophosphonate nucleotide derivatives |
| US5284837A (en) * | 1988-05-06 | 1994-02-08 | Medivir Ab | Derivatives of purine, process for their preparation and a pharmaceutical preparation |
| EP0353955A3 (en) * | 1988-08-02 | 1991-08-14 | Beecham Group Plc | Novel compounds |
| US5744600A (en) * | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
| US4966895A (en) * | 1989-02-02 | 1990-10-30 | Merck & Co. Inc. | Cyclic monophosphates of purine and pyrimidine acyclonucleosides as anti-retroviral agents |
| US5688778A (en) * | 1989-05-15 | 1997-11-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nucleoside analogs |
| GB8912043D0 (en) * | 1989-05-25 | 1989-07-12 | Beecham Group Plc | Novel compounds |
| US5302585A (en) * | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| CS276072B6 (en) * | 1990-08-06 | 1992-03-18 | Ustav Organicke Chemie A Bioch | (2R)-2-/DI(2-PROPYL)PHOSPHONYLMETHOXY/-3-p-TOLUENESULFONYLOXY -1- TRIMETHYLACETOXYPROPANE AND PROCESS FOR PREPARING THEREOF |
| WO1992002511A1 (en) * | 1990-08-10 | 1992-02-20 | Bristol-Myers Squibb Company | Novel process for the preparation of nucleotides |
| DE69129650T2 (de) * | 1990-09-14 | 1999-03-25 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha | Wirkstoffvorläufer von Phosphonaten |
| US5208221A (en) * | 1990-11-29 | 1993-05-04 | Bristol-Myers Squibb Company | Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives |
| US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| US5514798A (en) * | 1993-06-02 | 1996-05-07 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
| US5656745A (en) * | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| WO1995007919A1 (en) * | 1993-09-17 | 1995-03-23 | Gilead Sciences, Inc. | Method for dosing therapeutic compounds |
| DE4408534A1 (de) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden |
| US6465650B1 (en) | 1995-03-13 | 2002-10-15 | Aventis Pharma Deutschland Gmbh | Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids |
| US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| US5877166A (en) * | 1996-04-29 | 1999-03-02 | Sri International | Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents |
| DE122005000041I2 (de) * | 1996-07-26 | 2012-05-24 | Gilead Sciences Inc | Nukleotidanaloga. |
| US5733788A (en) * | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| KR100707505B1 (ko) * | 1997-07-25 | 2007-04-16 | 길리애드 사이언시즈, 인코포레이티드 | (r)-9-[(2-포스포노메톡시)프로필]아데닌(ρμρα)의 제조 방법 |
| AU2645199A (en) * | 1998-11-18 | 2000-06-05 | Viktor Veniaminovich Tets | Dialkyl-1-aryl-1-(2,4-dioxo-5-amino-1,3-pyrimidin-5-yl)methy lphosphonates |
| US7205404B1 (en) | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| SI1301519T1 (sl) | 2000-07-21 | 2015-07-31 | Gilead Sciences, Inc. | Predzdravila fosfonatnih nukleotidnih analogov in postopki za izbiro in izdelavo le-teh |
| ES2564144T3 (es) | 2001-06-29 | 2016-03-18 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Derivados de 6-[2-(fosfonometoxi)alcoxi] pirimidina que tienen actividad antivírica |
| US7388002B2 (en) | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| CA2466301A1 (en) * | 2001-11-14 | 2003-10-23 | Biocryst Pharmaceuticals, Inc. | Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
| US7214668B2 (en) * | 2002-05-13 | 2007-05-08 | Metabasis Therapeutics, Inc. | Phosphonic acid based prodrugs of PMEA and its analogues |
| JP4332496B2 (ja) * | 2002-05-13 | 2009-09-16 | メタバシス・セラピューティクス・インコーポレイテッド | Ｐｍｅａおよびｐｍｐａ環生成合成 |
| AU2003284800A1 (en) * | 2002-11-12 | 2004-06-03 | Tianjin Kinsly Pharmaceutical Co., Ltd. | A new crystal form of adefovir dipivoxil and its composition |
| CA2512475C (en) | 2003-01-14 | 2009-06-02 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| CN1805966B (zh) * | 2003-06-16 | 2013-03-13 | 捷克科学院有机化学和生物化学研究所 | 作为抗病毒核苷酸类似物的含膦酸酯基团的嘧啶化合物 |
| EP1656387A2 (en) * | 2003-07-30 | 2006-05-17 | Gilead Sciences, Inc. | Nucleobase phosphonate analogs for antiviral treatment |
| CA2565966A1 (en) * | 2004-06-08 | 2005-12-29 | Metabasis Therapeutics, Inc. | Lewis acid mediated synthesis of cyclic esters |
| CN100338080C (zh) * | 2004-06-16 | 2007-09-19 | 山东中科泰斗化学有限公司 | 9－[2－(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法 |
| UA93354C2 (ru) | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
| ES2401285T3 (es) | 2004-12-16 | 2013-04-18 | The Regents Of The University Of California | Fármacos con el pulmón como diana |
| WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
| TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| NZ594105A (en) | 2005-07-25 | 2013-02-22 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US7737273B2 (en) * | 2005-07-26 | 2010-06-15 | Hetero Drugs Limited | Process for acyclic phosphonate nucleotide analogs |
| CA2624333A1 (en) * | 2005-10-11 | 2007-04-19 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis c viral replication |
| JP5231242B2 (ja) * | 2005-12-14 | 2013-07-10 | シプラ・リミテッド | ヌクレオチド及びヌクレオシド系逆転写酵素阻害剤（テノホビル及びラミブジン）を剤形の異なる部分に含む医薬組合せ |
| FR2908133B1 (fr) * | 2006-11-08 | 2012-12-14 | Centre Nat Rech Scient | Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux |
| PT2514750E (pt) | 2007-06-18 | 2014-01-23 | Sunshine Lake Pharma Co Ltd | Tiazolil dihidropirimidinas substituídas com bromo-fenilo |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| WO2009120358A1 (en) * | 2008-03-27 | 2009-10-01 | Nektar Therapeutics | Oligomer-nitrogenous base conjugates |
| US7935817B2 (en) * | 2008-03-31 | 2011-05-03 | Apotex Pharmachem Inc. | Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof |
| US8048862B2 (en) * | 2008-04-15 | 2011-11-01 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| TW201010692A (en) | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
| EP2358736A1 (en) * | 2008-10-15 | 2011-08-24 | Intermune, Inc. | Therapeutic antiviral peptides |
| WO2010075549A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| SG172363A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Synthesis of purine nucleosides |
| NZ617066A (en) | 2008-12-23 | 2015-02-27 | Gilead Pharmasset Llc | Nucleoside analogs |
| EP2411392B1 (en) | 2009-03-26 | 2014-02-26 | Daewoong Pharmaceutical Co., Ltd. | Novel crystal forms of adefovir dipivoxil and processes for preparing the same |
| CN102741270B (zh) * | 2009-09-28 | 2015-07-22 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
| TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
| ES2516466T3 (es) | 2010-03-31 | 2014-10-30 | Gilead Pharmasset Llc | Síntesis estereoselectiva de agentes activos que contienen fósforo |
| WO2011156594A2 (en) | 2010-06-09 | 2011-12-15 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment |
| ES2551738T3 (es) | 2010-06-11 | 2015-11-23 | Gilead Sciences, Inc. | Formulaciones tópicas antivirales para la prevención de la transmisión del VHS-2 |
| CN103338754A (zh) | 2010-12-10 | 2013-10-02 | 西格玛制药实验有限责任公司 | 口服活性核苷酸类似物或口服活性核苷酸类似物前药的高度稳定组合物 |
| WO2012154698A2 (en) * | 2011-05-06 | 2012-11-15 | Mckenna Charles E | Method to improve antiviral activity of nucleotide analogue drugs |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| KR102186030B1 (ko) | 2012-10-29 | 2020-12-03 | 시플라 리미티드 | 항 바이러스성 포스포네이트 유사체 및 이의 제조를 위한 방법 |
| KR20150130355A (ko) | 2013-03-15 | 2015-11-23 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 비환식 뉴클레오사이드 포스포네이트 디에스테르 |
| US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
| US10167302B2 (en) * | 2014-05-23 | 2019-01-01 | University College Cork | Phosphonate nucleosides useful in the treatment of viral diseases |
| JP2017520545A (ja) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
| ES2915381T3 (es) | 2014-09-15 | 2022-06-22 | Univ California | Análogos de nucleótidos |
| EP3350191B9 (en) | 2015-09-15 | 2021-12-22 | The Regents of the University of California | Nucleotide analogs |
| EP3372227A1 (en) | 2017-03-06 | 2018-09-12 | MH10 Spolka z ograniczona odpowiedzialnoscia | Tablet formulation of adefovir dipivoxil |
| US11970482B2 (en) | 2018-01-09 | 2024-04-30 | Ligand Pharmaceuticals Inc. | Acetal compounds and therapeutic uses thereof |
| AU2023310177A1 (en) | 2022-07-21 | 2025-03-06 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1523865A (en) * | 1974-09-02 | 1978-09-06 | Wellcome Found | Purine compunds and salts thereof |
| US4347360A (en) * | 1980-09-16 | 1982-08-31 | Ens Bio Logicals Inc. | Ring open nucleoside analogues |
| CS233665B1 (en) * | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
| GB2150570B (en) * | 1983-05-24 | 1987-04-08 | Stanford Res Inst Int | Novel antiviral agents |
| AU8092587A (en) * | 1986-11-18 | 1988-05-19 | Bristol-Myers Squibb Company | Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids |
-
1985
- 1985-04-25 CS CS853017A patent/CS263951B1/cs not_active IP Right Cessation
-
1986
- 1986-04-11 DK DK198601678A patent/DK173625B1/da not_active IP Right Cessation
- 1986-04-16 DE DE8686302822T patent/DE3686002T2/de not_active Expired - Lifetime
- 1986-04-16 AT AT86302822T patent/ATE78259T1/de not_active IP Right Cessation
- 1986-04-16 EP EP86302822A patent/EP0206459B1/en not_active Expired - Lifetime
- 1986-04-17 AU AU56328/86A patent/AU580151B2/en not_active Expired
- 1986-04-23 NZ NZ215925A patent/NZ215925A/xx unknown
- 1986-04-24 JP JP61093514A patent/JPS61275289A/ja active Granted
- 1986-04-24 CA CA000507444A patent/CA1295614C/en not_active Expired - Lifetime
- 1986-04-24 NO NO861621A patent/NO174510B/no unknown
- 1986-04-25 US US06/856,299 patent/US4808716A/en not_active Expired - Lifetime
- 1986-04-27 EG EG243/86A patent/EG18079A/xx active
-
1996
- 1996-12-05 HK HK213296A patent/HK213296A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EG18079A (en) | 1992-06-30 |
| DK173625B1 (da) | 2001-05-07 |
| HK213296A (en) | 1996-12-06 |
| DE3686002D1 (de) | 1992-08-20 |
| JPS61275289A (ja) | 1986-12-05 |
| NO861621L (no) | 1986-10-27 |
| JPH0433798B2 (Direct) | 1992-06-04 |
| US4808716A (en) | 1989-02-28 |
| ATE78259T1 (de) | 1992-08-15 |
| AU5632886A (en) | 1986-10-30 |
| EP0206459A2 (en) | 1986-12-30 |
| CS263951B1 (en) | 1989-05-12 |
| DK167886D0 (da) | 1986-04-11 |
| AU580151B2 (en) | 1989-01-05 |
| EP0206459A3 (en) | 1987-05-20 |
| EP0206459B1 (en) | 1992-07-15 |
| NO174510C (Direct) | 1994-05-18 |
| DE3686002T2 (de) | 1992-12-17 |
| NZ215925A (en) | 1989-01-27 |
| DK167886A (da) | 1986-10-26 |
| CA1295614C (en) | 1992-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO174510B (no) | Anlogifremgangsmaate for fremstilling av terapeutisk aktivt 9-(2- fosfonylmethoxyethyl)-adenin | |
| EP0074306B1 (en) | Anti-viral guanine derivatives | |
| AU600002B2 (en) | N-phosphonylmethoxyalkyl pyrimidines and purines and therapeutic application thereof | |
| US5733896A (en) | N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, their preparation and use | |
| EP0145739B1 (en) | Novel antiviral agents | |
| Rosenberg et al. | Phosphonylmethoxyalkyl and phosphonylalkyl derivatives of adenine | |
| EP0138656B1 (en) | Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides, their preparation and their application in anti-viral compositions | |
| Parikh et al. | Analogs of Nucleotides. II. Phosphonate Esters of Ribose and Glucopyranosyl Purine Derivatives1 | |
| Jie et al. | 5'-O-phosphonomethyl-2', 3'-dideoxynucleosides: synthesis and anti-HIV activity | |
| US3238191A (en) | Phosphonic acid analogs of nucleoside phosphates and method | |
| WO1988005438A1 (en) | Antiviral agents | |
| Endová et al. | 2′, 3′-O-Phosphonoalkylidene derivatives of ribonucleosides: Synthesis and reactivity | |
| Holý | Synthesis of 3-amino-and 3-azidoanalogs of 9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine (HPMPA) | |
| DK149026B (da) | Analogifremgangsmaade til fremstilling af adeninnucleosidderivater | |
| US3541079A (en) | Process for the manufacture of nucleosides | |
| US2815342A (en) | Synthesis of pyrimidine nucleoside phosphates | |
| CA1287832C (en) | Anti-viral compounds | |
| CA1257256A (en) | Antiviral agents | |
| Ukita et al. | Organic Phosphates. XVIII. Syntheses of Lyxouridine 2', 3'-Cyclic Phosphate and Related Compounds. | |
| USH346H (en) | Process for making compounds possessing anticholinesterase activity | |
| 浮田忠之進 et al. | Organic Phosphates. XVIII. Syntheses of Lyxouridine 2', 3'-Cyclic Phosphate and Related Compounds. | |
| CS264223B1 (cs) | Způsob výroby N-(2-fosfonylmethoxyethyl)derivátů heterocykiických bází | |
| CS248003B2 (cs) | Způsob výroby derivátů 9-hydroxyethoxymethylguaninu |